FOCL Revenue Flow
Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.
- 2026-06-30: Revenue $13.20M; Cost of revenue $5.87M; Research and development $2.32M; Operating expenses (m).
- 2026-03-31: Revenue $17.81M; Cost of revenue $9.67M; Research and development $2.60M; Operating expenses $15.51M.
- 2025-06-30: Revenue $9.51M; Cost of revenue $4.65M; Research and development $2.29M; Operating expenses (m).
- 2025-03-31: Revenue $14.27M; Cost of revenue $8.27M; Research and development $2.58M; Operating expenses $12.30M.
Product or service
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Geography
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Statement Operating Activities Segment
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Timing Of Transfer Of Good Or Service
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.
Historical revenue and expense breakdown
Revenue and expense 3 month
| Period end | Revenue | Cost of revenue | Research and development | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|---|
| 2026-06-30 | $13.20M | $5.87M | $2.32M | (m) | $8.00K | -$14.49M |
| 2026-03-31 | $17.81M | $9.67M | $2.60M | $15.51M | $145.00K | -$9.08M |
| 2025-06-30 | $9.51M | $4.65M | $2.29M | (m) | $14.00K | -$6.41M |
| 2025-03-31 | $14.27M | $8.27M | $2.58M | $12.30M | $144.00K | -$7.44M |
Revenue and expense 6 month
| Period end | Revenue | Cost of revenue | Research and development | Income tax | Net income |
|---|---|---|---|---|---|
| 2026-06-30 | $24.80M | $11.50M | $4.78M | $25.00K | -$23.57M |
| 2025-06-30 | $16.01M | $7.99M | $4.65M | $23.00K | -$13.85M |
Revenue and expense 12 month
| Period end | Revenue | Cost of revenue | Research and development | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|---|
| 2025-12-31 | $70.53M | $40.53M | $9.66M | $54.70M | $438.00K | -$29.25M |
| 2024-12-31 | $69.39M | $40.65M | $8.36M | $50.97M | $313.00K | -$20.58M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |
| Outset Medical, Inc. (OM) | United States | $0.059B | -1.09 |
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B | |
| QT IMAGING HOLDINGS, INC. (QTI) | United States | $0.037B |